ATE330616T1 - Verabreichung von bisphosphonaten durch inhalation zur behandlung von knochenresorption und osteoporosis - Google Patents

Verabreichung von bisphosphonaten durch inhalation zur behandlung von knochenresorption und osteoporosis

Info

Publication number
ATE330616T1
ATE330616T1 AT02769132T AT02769132T ATE330616T1 AT E330616 T1 ATE330616 T1 AT E330616T1 AT 02769132 T AT02769132 T AT 02769132T AT 02769132 T AT02769132 T AT 02769132T AT E330616 T1 ATE330616 T1 AT E330616T1
Authority
AT
Austria
Prior art keywords
treatment
inhalation
administration
osteoporosis
bisphosphonates
Prior art date
Application number
AT02769132T
Other languages
English (en)
Inventor
Nageswara R Palepu
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE330616T1 publication Critical patent/ATE330616T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT02769132T 2001-05-02 2002-05-02 Verabreichung von bisphosphonaten durch inhalation zur behandlung von knochenresorption und osteoporosis ATE330616T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84782701A 2001-05-02 2001-05-02

Publications (1)

Publication Number Publication Date
ATE330616T1 true ATE330616T1 (de) 2006-07-15

Family

ID=25301603

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02769132T ATE330616T1 (de) 2001-05-02 2002-05-02 Verabreichung von bisphosphonaten durch inhalation zur behandlung von knochenresorption und osteoporosis

Country Status (11)

Country Link
US (2) US6743414B2 (de)
EP (1) EP1392325B1 (de)
JP (1) JP2004528365A (de)
CN (1) CN100345549C (de)
AT (1) ATE330616T1 (de)
BR (1) BR0209360A (de)
CA (1) CA2444718A1 (de)
DE (1) DE60212621T2 (de)
ES (1) ES2268086T3 (de)
PT (1) PT1392325E (de)
WO (1) WO2002089816A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
AU2007324044A1 (en) * 2006-11-21 2008-05-29 Teikoku Pharma Usa, Inc. Biphosphonate inhalant formulations and methods for using the same
US20080182823A1 (en) * 2007-01-26 2008-07-31 Hidesmasa Katsumi Polymer-linked-biophosphonate inhalant formulations and methods for using the same
US20100034752A1 (en) * 2008-08-11 2010-02-11 Toru Hibi Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
AU2010278860B2 (en) 2009-07-31 2016-05-26 Thar Pharma, Llc Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
CN105640924B (zh) * 2016-01-18 2018-11-02 杭州旦杰医学科技有限公司 用于呼吸道给药的阿仑膦酸钠粉雾剂及其制备方法和用途
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
CN111053761B (zh) * 2020-01-16 2022-05-03 杭州旦承医药科技有限公司 一种吸入用双膦酸类药物及其制备方法及其在慢性阻塞性肺疾病的用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE182C (de) * 1877-08-02 A. LANGE & SÖHNE in Glashütte, Sachsen Sekundenwerk mit springendem Zeiger
US4405598A (en) * 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5183815A (en) * 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
CA2122479C (en) * 1991-11-22 1998-08-25 Richard John Dansereau Risedronate delayed-release compositions
ATE176476T1 (de) * 1992-12-02 1999-02-15 Hoechst Ag Guanidinalkyl-1, 1-bisphosphonsäurederivate, verfahren zu ihrer herstellung und ihre verwendung
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
KR19980702210A (ko) * 1995-02-17 1998-07-15 폴락 돈나 엘 비척추골 골절의 위험률을 감소시키는 방법
IL118422A0 (en) * 1995-06-02 1996-09-12 Merck & Co Inc Use of alendronate for the prevention of osteoporosis
US5686114A (en) * 1995-06-02 1997-11-11 University Of Iowa Research Foundation Uses of inorganic pyrophosphates
ATE289199T1 (de) * 1995-06-06 2005-03-15 Merck & Co Inc Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
EP1151752A3 (de) * 1997-07-22 2002-12-18 MERCK & CO. INC. Methoden zur Hemmung der Knochenresorption
DE19828450A1 (de) * 1998-06-26 1999-12-30 Hassan Jomaa Bisphosphonsäuren und deren Derivate enthaltende Arzneimittel zur Prophylaxe und zur Behandlung von Autoimmunkrankheiten sowie von Allergien
US6008207A (en) * 1998-08-13 1999-12-28 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
US6414006B1 (en) * 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
IL143046A0 (en) * 1998-11-12 2002-04-21 Pilkiewicz Frank G An inhalation system
US6482411B1 (en) * 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods

Also Published As

Publication number Publication date
DE60212621T2 (de) 2007-06-14
JP2004528365A (ja) 2004-09-16
CN1505517A (zh) 2004-06-16
BR0209360A (pt) 2004-06-08
CA2444718A1 (en) 2002-11-14
US6743414B2 (en) 2004-06-01
US20040127466A1 (en) 2004-07-01
US20030064966A1 (en) 2003-04-03
PT1392325E (pt) 2006-10-31
EP1392325B1 (de) 2006-06-21
CN100345549C (zh) 2007-10-31
ES2268086T3 (es) 2007-03-16
EP1392325A1 (de) 2004-03-03
DE60212621D1 (de) 2006-08-03
WO2002089816A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
CY1106482T1 (el) Φαρμακευτικη παρεντepικη συνθεση πepιεχοντας ενα διφωσφονικο
ATE500218T1 (de) Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff
DK1233770T3 (da) Phosphonatforbindelser
CL2003001743A1 (es) Compuestos derivados de leucinamida, inhibidores de la cisteina proteasa; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y su uso en el tratamiento de la osteoporosis, enfermedad de paget's, peridontal, perdida
MY146809A (en) Treatment and prevention of osteoporosis
FI964315A0 (fi) Bisfosfonihappojen märkärakeistusformulointi
ATE330616T1 (de) Verabreichung von bisphosphonaten durch inhalation zur behandlung von knochenresorption und osteoporosis
ATE232874T1 (de) Prostaglandin-konjugate zur behandlung von knochenkrankheiten
WO2004058235A3 (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative
EP0341961A3 (de) Polymalonsäuren als Knochenaffinitätsagent
IS4392A (is) Pýridýlbisfosfónöt til notkunar sem efni til lækninga
BR9808233A (pt) Preparação farmacêutica

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1392325

Country of ref document: EP